Session Information
2006 Midyear Clinical Meeting
Click here to go to the previous page
Debates in Therapeutics 2006
Track:
Sessions
Program Code: 215-L01
Date: Monday, December 4, 2006
Time: 2:00 PM to 5:00 PM
Location:
Ballroom B (CC)
MODERATOR:
Melinda M. Neuhauser, Pharm.D., Clinical Pharmacy Specialist, Infectious Diseases, Department Veterans Affairs, Pharmacy Benefits Management & Strategic Health Group, Hines, IL, Clinical Pharmacy Specialist, Infectious Diseases, Department Veterans Affairs, Pharmacy Benefits Management & Strategic Health Group
SPEAKER(S):
Laura Boehnke Michaud, Pharm.D., BCOP, Disease Site Supervisor and Clinical Coordinator, The University of Texas M. D. Anderson Cancer Center, Houston
Viewpoint B: Tamoxifen [Prevention of Breast Cancer in High Risk Postmenopausal Women: Raloxifene vs. Tamoxifen]
John D. Cleary, Pharm.D., Professor and Associate Director, Mycotic Research Center, University of Mississippi Schools of Medicine and Pharmacy, Jackson
Viewpoint A: Echinocandins [Treatment for Invasive Candidiasis: Echinocandins vs. Fluconazole]
Russell E. Lewis, Pharm.D., FCCP, BCPS, Associate Professor, University of Houston College of Pharmacy, Houston, Texas
Viewpoint B: Fluconazole [Treatment for Invasive Candidiasis: Echinocandins vs. Fluconazole]
Dr. Jane Pruemer, PharmD, BCOP, Professor of Clinical Pharmacy Practice, University of Cincinnati College of Pharmacy
Viewpoint A: Raloxifene [Prevention of Breast Cancer in High Risk Postmenopausal Women: Raloxifene vs. Tamoxifen]
Jill A. Rebuck, Pharm.D., BCPS, Critical Care Clinician, Fletcher Allen Health Care, Burlington, VT
Viewpoint A: Pro [Off-Label Recombinant Factor VIIa in the Setting of Emergent Intracerebral Hemorrhage: Pro vs. Con]
Denise H. Rhoney, Pharm.D., Associate Professor, Wayne State University, Department of Pharmacy Practice, Detroit, MI
Viewpoint B: Con [Off-Label Recombinant Factor VIIa in the Setting of Emergent Intracerebral Hemorrhage: Pro vs. Con]
Rowena N. Schwartz, Pharm.D., BCOP, Director of Oncology and Weinberg Pharmacy, The Johns Hopkins Hospital, Department of Pharmacy Services, Baltimore, MD
Viewpoint A: Triple Upfront [Treatment of CINV: Triple Upfront vs. Traditional Therapy]
Michael D. Westmoreland, Pharm.D., Disease Site Supervisor, The University of Texas M. D. Anderson Cancer Center, Houston
Viewpoint B: Traditional Therapy [Treatment of CINV: Triple Upfront vs. Traditional Therapy]
Description
Learning Objectives: Discuss why therapeutic controversy may occur. Identify four therapeutic areas where controversy exists. Describe the pros and cons of selected therapeutic issues.